Skip to main content
JUBILANT PHARMOVA LIMITED logo

JUBILANT PHARMOVA LIMITED — Investor Relations & Filings

Ticker · JUBLPHARMA ISIN · INE700A01033 LEI · 335800C6LDKWF4HQH833 BSE.NS Manufacturing
Open in API
Filings indexed 1,045 across all filing types
Latest filing 2023-10-27 Earnings Release
Country IN India
Listing BSE.NS JUBLPHARMA

About JUBILANT PHARMOVA LIMITED

https://www.jubilantpharmova.com/

Jubilant Pharmova Limited is an integrated global pharmaceutical company operating through three primary segments: Pharmaceuticals, Contract Research and Development Services (CRDS), and Proprietary Novel Drugs. The Pharmaceuticals segment specializes in radiopharmaceuticals for nuclear medicine, allergy immunotherapy, and the development and manufacturing of generic formulations. It also provides Contract Development and Manufacturing Organization (CDMO) services for sterile injectables and non-sterile products. The CRDS division offers comprehensive drug discovery and development solutions to biopharmaceutical companies worldwide. Furthermore, the Proprietary Novel Drugs segment focuses on creating innovative therapies for oncology and autoimmune diseases. The company leverages its advanced manufacturing infrastructure and research capabilities to serve global markets with a focus on complex chemistry and specialized healthcare solutions.

Recent filings

Filing Released Lang Actions
Press Release
Earnings Release Classification · 95% confidence The document is a press release dated October 27, 2023, announcing the financial results for the quarter ended September 30, 2023 (Q2 FY24). It includes detailed financial data such as revenue, EBITDA, profit before tax, and segment-wise financial highlights. The document references Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which pertains to disclosure of material events including financial results. The content is a comprehensive earnings announcement with financial performance highlights and business segment analysis, typical of an Earnings Release. It is not a full annual or interim report, nor a transcript or presentation alone, but a press release with financial results. The length (15,000 characters) and detailed financial data confirm it is not merely an announcement of a report but the actual earnings release document. Therefore, the appropriate classification is Earnings Release (ER). Q2 2024
2023-10-27 English
Change in Director(s)
Regulatory Filings
2023-10-27 English
Outcome of Board Meeting
Interim / Quarterly Report Classification · 100% confidence The document is a detailed announcement from Jubilant Pharmova Limited dated October 27, 2023, addressed to stock exchanges and shareholders. It reports the outcome of a Board Meeting held on the same day. The key points include approval of unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2023, along with the limited review report by statutory auditors. It also announces the resignation of a director and appointment of a new director. The document includes the unaudited financial results and the auditor's limited review report, as well as disclosures related to board changes. The presence of unaudited financial results and the limited review report for a quarter and half year period indicates this is an Interim / Quarterly Report. The document is not merely an announcement of a report but contains substantive financial data and analysis. Therefore, the appropriate classification is Interim / Quarterly Report (IR).
2023-10-27 English
Financial Result Updates
Interim / Quarterly Report Classification · 95% confidence The document is a detailed announcement from Jubilant Pharmova Limited dated October 27, 2023, addressed to stock exchanges and shareholders. It reports the outcome of a Board Meeting held on the same day. The key points include approval of unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2023, along with the limited review report by statutory auditors. It also announces the resignation of a director and appointment of a new director. The document includes the resignation letter, auditor's review report, and detailed disclosures about the board changes. The presence of unaudited financial results and the auditor's limited review report for the quarter and half year indicates this is an Interim / Quarterly Report. The document is comprehensive and contains substantive financial data and analysis, not just an announcement or certification. Therefore, it fits the definition of an Interim / Quarterly Report (IR).
2023-10-27 English
Loss of Share Certificates
Regulatory Filings Classification · 100% confidence The document is a compliance notice under Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, regarding a lost share certificate and the issuance of a duplicate certificate. It is an official regulatory announcement to stock exchanges about a share certificate issue, not a financial report, earnings release, or management information. The document is short (1888 characters) and serves as a regulatory compliance filing. Therefore, it fits best under Regulatory Filings (RNS).
2023-10-26 English
Loss of Share Certificates
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges regarding compliance with SEBI regulations about a lost share certificate and the issuance of a duplicate certificate. It informs the exchanges to caution members against dealing with the reported shares. There is no financial data, report, or detailed analysis present. The document is a regulatory compliance announcement related to share certificate status, not a financial report or meeting material. It fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2023-10-20 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.